Map of Zimbabwe highlighting the districts detected as persistent hotspots of <i>S. haematobium</i> prevalence (PPHS), persistent hotspots of decreased praziquantel efficacy (EPHS)... by Takafira Mduluza (39754)

Fluctuation trend of the mean temperature index. by Chengyuan Hao (21615653)

“…Secondly, the daily minimum and maximum temperatures increased significantly, which were 0.395°C/10a and 0.200°C/10a respectively<b>—</b>less than the national mean. …”

Variation curve of the mean temperature index. by Chengyuan Hao (21615653)

“…Secondly, the daily minimum and maximum temperatures increased significantly, which were 0.395°C/10a and 0.200°C/10a respectively<b>—</b>less than the national mean. …”

Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index. by Søren Egstrand (10906087)

“…All groups were compared by Kruskal Wallis test with <i>post hoc</i> test after Dunn with Bonferroni adjustment showing significant decreased Ki-67 labeling index of <i>Cina1</i> compared to <i>Cina2</i> (p = 0.006) and the untreated CKD groups (p = 0.0001 and p = 0.0002, respectively). …”

Forest plots illustrate the mean difference in; (A) hospital stay, (B) ICU stay, (C) intubation time; with subgroup analysis. by Mohamed R. Abdelraouf (21501468)

Mean (95% CI) and standard deviation of Co-Contraction index of right and left gluteus medius (MVC%) during 60 minutes standing between two groups. by Saeedeh Abbasi (9423189)

The mean number of the emerged <i>D. melanogaster</i> adults. Mean number (±SE) of emerged adults and average percentage (±SE) of the residual fertility at the different treatment... by Flavia Cerasti (21655934)

Heatmaps of the top 536 differentially expressed genes (DEG) by calcitriol in CaSki cells with fold changes ranging from 1.5 to −1.5. by Euclides Avila (41023)

Maximum likelihood estimates of trans-log mean stochastic function. by James Anaba Akolgo (14129379)

Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Study selection criteria. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

Subjects:

Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

Subjects:

PICOS criteria for the SLR. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

PRISMA flow chart. by Filip Stanicic (17808254)

Subjects: